SCHEMBL6183698

SCHEMBL6183698

CC(C)Cc1cc(-c2ccc(Cn3c(-c4ccccc4)nc(Cl)c3C=O)c(Cl)c2)c(NS(=O)(=O)C(C)(C)C)s1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MAS1 P04201 1/20 0.45
▸ AGTR2 P50052 12/20 0.36
▸ ALOX5AP P20292 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183402 0.91 MAS1 (0.54) MAS1AGTR2
SCHEMBL6185055 0.81 MAS1 (0.46) MAS1AGTR2
SCHEMBL7383678 0.79 MAS1 (0.55) MAS1AGTR2
SCHEMBL3905659 0.77 MAS1 (0.55) MAS1AGTR2
SCHEMBL29769813 0.77 MAS1 (0.55) MAS1AGTR2
SCHEMBL5173529 0.76 ALOX5AP (0.43) ALOX5AP
SCHEMBL3902365 0.75 MAS1 (0.55) MAS1AGTR2
SCHEMBL5175143 0.74 PTGES2 (0.39) ALOX5AP
SCHEMBL24637566 0.73 MAS1 (0.83) MAS1AGTR2
SCHEMBL7690753 0.72 PTGES2 (0.38) MAS1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1185527-B1 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS AVENTIS PHARMA GMBH (DE) 2005-07-27 — — EP disclosed
US-6429222-B2 HYPOTENSIVE AGENT, ENDOTHELIAL DAMAGE, ARTERIOSCLEROSIS, ANTIDIABETIC AGENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-08-06 — — US disclosed
US-20020077344-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2002-06-20 — — US disclosed
US-20010018449-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2001-08-30 — — US disclosed
US-6235766-B1 HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018449-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them AGTR1, NPR1, EDNRB MAS1 362/4885AGTR2 7/4885ALOX5AP 1910/4885
US-20020077344-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them AGTR1, NPR1, EDNRB MAS1 427/4885AGTR2 8/4885ALOX5AP 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback